Barclays PLC Neurocrine Biosciences Inc Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Barclays PLC holds 178,368 shares of NBIX stock, worth $21.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
178,368
Previous 181,591
1.77%
Holding current value
$21.2 Million
Previous $20.9 Million
16.37%
% of portfolio
0.01%
Previous 0.01%
Shares
30 transactions
Others Institutions Holding NBIX
# of Institutions
654Shares Held
96.5MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.69 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.21 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$583 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$359 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$302 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...